This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- After an ugly week, all we can do is look forward, Jim Cramer told his "Mad Money" TV show viewers Friday. That's why his game plan for next week's trading focuses on earnings and the upcoming Federal Reserve meeting on Tuesday and Wednesday.

Cramer said he'll be starting his week watching the rest of the world, with fresh economic data coming in from China and Europe. He said either of these reports could spark an over-sold rally on Monday. Cramer was also bullish on both Sprint (S) and T-Mobile US (TMUS) on the latest rumors a merger could be brewing.

Then, on Tuesday, Cramer said all eyes will be on the Fed, which will likely begin talking about easing its bond buying as all of the recent economic news has been very bullish. Also on the menu: Jabil Circuit (JBL), the part supplier that could tip us to how Apple (AAPL) products are selling. Cramer currently owns shares of Apple for his charitable trust, Action Alerts PLUS.

For Wednesday, it's earnings from FedEx (FDX), a stock that's rebounding along with economic growth, General Mills (GIS) a stock that's now just marking time as interest rates creep higher, and home builder Lennar (LEN), which should have decent numbers but will likely fall anyway. Cramer was bearish on Oracle (ORCL), which also reports Wednesday.

Next, on Thursday, more earnings from ConAgra (CAG), a stock Cramer said it too risky; Darden Restaurants (DRI), a stock worth buying if it gets hit; and two retail plays, Nike (NKE) and Pier 1 Imports (PIR), both Cramer faves.

Finally, on Friday, we reach the finish line with, well, Finish Line (FINL). Cramer said he'd be a buyer of this stock on Thursday ahead of its results.

Executive Decision: Tarek Sherif

For his "Executive Decision" segment, Cramer sat down with Tarek Sherif, chairman and CEO of Medidata Solutions (MDSO), the cloud computing company for clinical development whose shares soared 193% in 2013 and over 50% since Cramer last spoke with Sherif in July.

Sherif once again explained that drug makers currently spend over $90 billion a year bringing new drugs to market, and that process is only getting more and more complicated as new regulations and safety concerns couple with more and more complex drugs. In that environment, traditional in-house software just isn't flexible enough, he said, which is why the cloud computing model makes so much sense.

Sherif said Medidata's platform allows drug makers to get drugs to market sooner with increased safety and at lower costs by increasing the productivity and efficiency of their clinical trials.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs